Detection of PD-1 inhibitory signaling and its molecular relays in T cells: Implications for cancer immunotherapy

T 细胞中 PD-1 抑制信号传导及其分子中继的检测:对癌症免疫治疗的影响

基本信息

项目摘要

PD-1 blocking agents have achieved significant success as anti-cancer therapeutics. The mechanism(s) of how PD-1 compromises anti-tumor function remain poorly understood. Although in trans engagement of PD-1 expressed in T cells by its ligands expressed on APC or cancer cells inhibits T cell activation, evolving discoveries provide evidence that PD-L1:B7-1(CD80) in cis and PD-1:PD-L1 in cis non-canonical interactions occur when these molecules are co-expressed on APC, and disrupt the canonical interaction between PD-1 and PD-L1 in trans and T cell inhibitory signaling. Thus, expression of PD-L1 in the tumor microenvironment (TME) is not synonymous with PD-1-mediated T cell inhibition. We generated an antibody that recognizes PD-1pY248 (pPD-1), which is required for PD-1 inhibitory signaling, and detected pPD-1 in mouse and human. We found pPD-1+ T cells in cultures, in mouse tumor models and patient biopsies, but also in CD8+ T central memory (TCM) cells in the peripheral blood of healthy individuals. In tumor bearing mice, pPD-1 was expressed in tumor infiltrating CD8+ T lymphocytes but mostly in Treg. We generated mice with conditional targeting of Pdcd1 gene (PD-1f/f) and selectively eliminated PD-1 in Treg (Pdcd1f/fFoxP3cre). In tumor-bearing Pdcd1f/fFoxP3cre mice, Treg displayed enrichment in pathways regulating lipid metabolism, fatty acid oxidation, and production of monocyte/macrophage chemotactic protein-1 (MCP-1) and GABAergic neurotransmitter with known immunosuppressive function. These features correlated with a significant increase of B cells and M2-like macrophages, diminished activation of tumor infiltrating T cells, and increased tumor growth. Our results reveal a previously unappreciated network by which Treg-selective blockade of PD-1 signaling reshapes the immunological landscape and suggest that abrogation of PD-1 signaling in distinct cell types differentially impacts the TME. Our findings indicate that pPD-1 is a powerful marker to identify T cells subjected to PD-1 inhibitory signaling and support the novel hypothesis that cell-specific detection of PD-1 signaling by pPD-1 might predict the outcome of checkpoint immunotherapy. To investigate these, we will pursue the following specific aims: 1. To identify the immunological and biochemical properties of pPD-1+ T cells in the context of cancer. We will characterize pPD-1+ CD8+ TIL and Treg by single cell immunoprofiling, and investigate how T cell subset- specific PD-1 signaling reshapes the TME by using our Pdcd1f/fCD8cre and Pdcd1f/fFoxP3cre mice. 2. To identify the molecular and functional properties of pPD-1+ cells in healthy individuals. We will examine how PD-1 signaling shapes the properties of T cells in healthy individuals and in cancer patients and uncover why only cancer-mediated PD-1 signaling induces TEX. 3. To determine expression, function and prognostic significance of pPD-1+ TIL in cancer patients. We will examine cell-specific PD-1 expression and signaling in patient biopsies, co-expression of PD-1/pPD-1, PD- L1 and CD80, and determine their prognostic significance.
PD-1阻断剂在抗癌治疗方面取得了显著的成功。机制(S) PD-1对抗肿瘤功能的影响仍知之甚少。尽管在PD-1的反式结合中 在T细胞中通过其配体表达在APC或癌细胞上表达抑制T细胞激活,不断发展的发现 提供证据表明顺式中的PD-L1:B7-1(CD80)和顺式中的PD-1:PD-L1发生非正则相互作用 这些分子在APC上共表达,并破坏PD-1和PD-L1之间的正则相互作用 反式和T细胞抑制信号转导。因此,PD-L1在肿瘤微环境(TME)中的表达不 与PD-1介导的T细胞抑制同义词。我们产生了一种识别PD-1pY248(PPD-1)的抗体, 它是PD-1抑制信号转导所必需的,并在小鼠和人中检测到PPD-1。我们发现了PPD-1+T 在培养物、小鼠肿瘤模型和患者活检组织中的细胞,也在CD8+T中央记忆(TCM)细胞中 健康人的外周血液。在荷瘤小鼠中,PPD-1在肿瘤浸润性CD8+中表达 T淋巴细胞,但主要分布在Treg。我们建立了条件靶向Pdcd1基因(PD-1f/f)的小鼠,并 选择性清除Treg(Pdcd1f/fFoxP3cre)中的PD-1。在荷瘤的Pdcd1f/fFoxP3cre小鼠中,Treg显示 在调节脂肪代谢、脂肪酸氧化和产生 单核/巨噬细胞趋化蛋白-1与GABA能神经递质的关系 免疫抑制功能。这些特征与B细胞和M2样细胞的显著增加有关 巨噬细胞,减少肿瘤浸润性T细胞的激活,促进肿瘤生长。我们的结果显示 一种以前不为人知的网络,通过它对PD-1信号的Treg选择性封锁重塑了 免疫学格局,并表明在不同类型的细胞中取消PD-1信号会产生不同的影响 TME。我们的发现表明,PPD-1是识别受PD-1抑制的T细胞的一个强有力的标志物 并支持新的假设,即PPD-1对PD-1信号的细胞特异性检测可以预测 检查点免疫治疗的结果。为了调查这些问题,我们将追求以下具体目标: 1.鉴定PPD-1+T细胞在癌症中的免疫学和生化特性。 我们将通过单细胞免疫图谱来鉴定PPD-1+CD8+TIL和Treg,并研究T细胞亚群如何- 特定的PD-1信号通过使用我们的Pdcd1f/fCD8cre和Pdcd1f/fFoxP3cre小鼠重塑TME。 2.鉴定健康人PPD-1+细胞的分子和功能特性。我们会 研究PD-1信号如何塑造健康人和癌症患者的T细胞特性 揭示为什么只有癌症介导的PD-1信号才能诱导TeX。 3.检测肿瘤患者外周血中PPD-1+TIL的表达、功能及预后意义。我们 将检测患者活检组织中细胞特异性PD-1的表达和信号,PD-1/PPD-1,PD-1,PD-1的共同表达 L1和CD80,并确定其预后意义。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

VASSILIKI A BOUSSIOTIS其他文献

VASSILIKI A BOUSSIOTIS的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('VASSILIKI A BOUSSIOTIS', 18)}}的其他基金

Understanding the cellular and functional changes in the immune tumor microenvironment of glioblastoma during progression and treatments.
了解胶质母细胞瘤在进展和治疗过程中免疫肿瘤微环境的细胞和功能变化。
  • 批准号:
    10681034
  • 财政年份:
    2023
  • 资助金额:
    $ 72.26万
  • 项目类别:
The effects of PD-1 on tumor-mediated “emergency” myelopoiesis and fate commitment of myeloid cells: Implications for anti-tumor immunity
PD-1 对肿瘤介导的“紧急”骨髓生成和骨髓细胞命运决定的影响:抗肿瘤免疫的意义
  • 批准号:
    10330481
  • 财政年份:
    2020
  • 资助金额:
    $ 72.26万
  • 项目类别:
The effects of PD-1 on tumor-mediated “emergency” myelopoiesis and fate commitment of myeloid cells: Implications for anti-tumor immunity
PD-1 对肿瘤介导的“紧急”骨髓生成和骨髓细胞命运决定的影响:抗肿瘤免疫的意义
  • 批准号:
    10547788
  • 财政年份:
    2020
  • 资助金额:
    $ 72.26万
  • 项目类别:
Advancing treatment outcomes in malignant glioma by integrating immunotherapy and standard of care using genetically engineered mice that recapitulate molecular feature of human glioma
通过使用重现人类神经胶质瘤分子特征的基因工程小鼠整合免疫疗法和护理标准来提高恶性神经胶质瘤的治疗效果
  • 批准号:
    10524100
  • 财政年份:
    2018
  • 资助金额:
    $ 72.26万
  • 项目类别:
Advancing treatment outcomes in malignant glioma by integrating immunotherapy and standard of care using genetically engineered mice that recapitulate molecular feature of human glioma
通过使用重现人类神经胶质瘤分子特征的基因工程小鼠整合免疫疗法和护理标准来提高恶性神经胶质瘤的治疗效果
  • 批准号:
    10198866
  • 财政年份:
    2018
  • 资助金额:
    $ 72.26万
  • 项目类别:
Advancing treatment outcomes in malignant glioma by integrating immunotherapy and standard of care using genetically engineered mice that recapitulate molecular feature of human glioma
通过使用重现人类神经胶质瘤分子特征的基因工程小鼠整合免疫疗法和护理标准来提高恶性神经胶质瘤的治疗效果
  • 批准号:
    10431932
  • 财政年份:
    2018
  • 资助金额:
    $ 72.26万
  • 项目类别:
Advancing Treatment Outcomes in Malignant Glioma by Integrating Immunotherapy and Standard of Care using Genetically Engineered Mice that Recapitulate Molecular Feature of Human Glioma
通过使用重现人类胶质瘤分子特征的基因工程小鼠整合免疫疗法和护理标准来提高恶性胶质瘤的治疗效果
  • 批准号:
    10377182
  • 财政年份:
    2018
  • 资助金额:
    $ 72.26万
  • 项目类别:
Improving anti-tumor T cell immunity by targeting LDH-A functions beyond the Warburg effect
通过超越 Warburg 效应靶向 LDH-A 功能来提高抗肿瘤 T 细胞免疫力
  • 批准号:
    9919516
  • 财政年份:
    2017
  • 资助金额:
    $ 72.26万
  • 项目类别:
Improving anti-tumor T cell immunity by targeting LDH-A functions beyond the Warburg effect
通过超越 Warburg 效应靶向 LDH-A 功能来提高抗肿瘤 T 细胞免疫力
  • 批准号:
    10152529
  • 财政年份:
    2017
  • 资助金额:
    $ 72.26万
  • 项目类别:
Effects of PGE2 on Reconstitution of Hematopoiesis and Immunity after UCBT
PGE2对UCBT后造血和免疫重建的影响
  • 批准号:
    8985871
  • 财政年份:
    2013
  • 资助金额:
    $ 72.26万
  • 项目类别:

相似海外基金

How Does Particle Material Properties Insoluble and Partially Soluble Affect Sensory Perception Of Fat based Products
不溶性和部分可溶的颗粒材料特性如何影响脂肪基产品的感官知觉
  • 批准号:
    BB/Z514391/1
  • 财政年份:
    2024
  • 资助金额:
    $ 72.26万
  • 项目类别:
    Training Grant
BRC-BIO: Establishing Astrangia poculata as a study system to understand how multi-partner symbiotic interactions affect pathogen response in cnidarians
BRC-BIO:建立 Astrangia poculata 作为研究系统,以了解多伙伴共生相互作用如何影响刺胞动物的病原体反应
  • 批准号:
    2312555
  • 财政年份:
    2024
  • 资助金额:
    $ 72.26万
  • 项目类别:
    Standard Grant
RII Track-4:NSF: From the Ground Up to the Air Above Coastal Dunes: How Groundwater and Evaporation Affect the Mechanism of Wind Erosion
RII Track-4:NSF:从地面到沿海沙丘上方的空气:地下水和蒸发如何影响风蚀机制
  • 批准号:
    2327346
  • 财政年份:
    2024
  • 资助金额:
    $ 72.26万
  • 项目类别:
    Standard Grant
Graduating in Austerity: Do Welfare Cuts Affect the Career Path of University Students?
紧缩毕业:福利削减会影响大学生的职业道路吗?
  • 批准号:
    ES/Z502595/1
  • 财政年份:
    2024
  • 资助金额:
    $ 72.26万
  • 项目类别:
    Fellowship
感性個人差指標 Affect-X の構築とビスポークAIサービスの基盤確立
建立个人敏感度指数 Affect-X 并为定制人工智能服务奠定基础
  • 批准号:
    23K24936
  • 财政年份:
    2024
  • 资助金额:
    $ 72.26万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Insecure lives and the policy disconnect: How multiple insecurities affect Levelling Up and what joined-up policy can do to help
不安全的生活和政策脱节:多种不安全因素如何影响升级以及联合政策可以提供哪些帮助
  • 批准号:
    ES/Z000149/1
  • 财政年份:
    2024
  • 资助金额:
    $ 72.26万
  • 项目类别:
    Research Grant
How does metal binding affect the function of proteins targeted by a devastating pathogen of cereal crops?
金属结合如何影响谷类作物毁灭性病原体靶向的蛋白质的功能?
  • 批准号:
    2901648
  • 财政年份:
    2024
  • 资助金额:
    $ 72.26万
  • 项目类别:
    Studentship
Investigating how double-negative T cells affect anti-leukemic and GvHD-inducing activities of conventional T cells
研究双阴性 T 细胞如何影响传统 T 细胞的抗白血病和 GvHD 诱导活性
  • 批准号:
    488039
  • 财政年份:
    2023
  • 资助金额:
    $ 72.26万
  • 项目类别:
    Operating Grants
New Tendencies of French Film Theory: Representation, Body, Affect
法国电影理论新动向:再现、身体、情感
  • 批准号:
    23K00129
  • 财政年份:
    2023
  • 资助金额:
    $ 72.26万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
The Protruding Void: Mystical Affect in Samuel Beckett's Prose
突出的虚空:塞缪尔·贝克特散文中的神秘影响
  • 批准号:
    2883985
  • 财政年份:
    2023
  • 资助金额:
    $ 72.26万
  • 项目类别:
    Studentship
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了